Ip Group Share News (IPO)

London close: Stocks mixed as UK economy returns to growth

(Sharecast News) - London markets finished with a mixed performance on Wednesday, following a surge on Tuesday, with investors buoyed by news of the UK economy's return to growth in January.

IP Group net asset value declines amid supply chain issues, inflation

(Alliance News) - IP Group PLC on Wednesday reported a slowed decline in net asset value, citing global issues such as supply chain disruptions and inflation and interest rate trends.

LONDON BROKER RATINGS: JPMorgan raises Flutter and cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

IP Group net asset value falls, but losses narrow

(Sharecast News) - Intellectual property-focussed investor IP Group reported a net asset value of £1.19bn in its results for 2023 on Wednesady, or 114.3p per share, down from £1.38bn and 132.9p per share in 2022.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: IP Group expects net assets to fall in 2023 trading update

IP Group PLC - invests in companies pursuing breakthrough science and innovation, such as Oxford Nanopore Technologies PLC - Expects net asset value per share on December 31 to fall to between 111 pence and 117p, from 132.9p a year earlier. Says this is due to the market environment for early-stage investing "remaining challenging in 2023 and, against this backdrop, we saw some further softening of valuations in the final quarter of 2023". Also says: "Within this context, many of the group's leading portfolio companies made strong progress, with some significant inflection points expected in 2024." Expects to announce its 2023 results on March 13.

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

IN BRIEF: IP Group takes part in portfolio company's funding round

IP Group PLC - invests in companies pursuing breakthrough science and innovation, such as Oxford Nanopore Technologies PLC - Notes its participation in a follow-on portfolio company funding round. Anticipates a net unrealised fair value gain of around GBP40 million or 4 pence per share as a result. Commits a total of USD15 million to the round, with completion expected in mid-January, though this is subject to certain conditions. Adds that it anticipates the gain for the transaction will be offset by other fair value reductions in its portfolio. However, it is "too early" to provide guidance on the carrying values of its portfolio companies at year-end.

IP Group commits £11.8m to portfolio company's funding round

(Sharecast News) - IP Group announced its participation in a follow-on funding round for an unnamed portfolio company on Friday, expecting to realise a net fair value gain of £40m, or 4p per share.

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

London close: Stocks make small gains in wake of rate decisions

(Sharecast News) - London stocks closed with minimal changes on Monday, following a week marked by significant central bank decisions.

IP Group launches £20m share buyback, shares jump

(Sharecast News) - IP Group surged on Monday as it announced the launch of a share buyback of up to £20m.

IN BRIEF: IP Group sets GBP20 million share buyback to cut cash pile

IP Group PLC - invests in companies pursuing breakthrough science and innovation, such as Oxford Nanopore Technologies PLC - Launches on Monday a share buyback worth up to GBP20 million. The programme conducted by Deutsche Numis, part of Deutche Bank AG, will run until the end of 2024. IP Group says it has gross cash of GBP235 million as of November 30, following GBP38 million in cash realisations. At the same time, the company notes the discount of its share price to net asset value, which was reported at 126.7 pence per share at the half-year stage of 2023 on June 30.

IN BRIEF: IP Group investee pens deal with Jazz Pharmaceuticals

IP Group PLC - Oxford, England-based intellectual property commercialisation - Says portfolio company Autifony Therapeutics Ltd has signed a deal with Jazz Pharmaceuticals PLC worth up to USD770 million for drug discovery and preclinical development on two ion channel targets associated with neurological disorders. Jazz will lead clinical development, manufacturing and regulatory activities and commercialisation once preclinical development is finalised. IP Group holds a 26% stake in Autifony, valued at GBP4.6 million.

UK dividends calendar - next 7 days